Advances in the treatment of prostate cancer have extended life expectancy ([@CIT0003], [@CIT0004], [@CIT0019]). Approximately 70% of the patients with advanced disease can be expected to develop skeletal metastases ([@CIT0005]).

The role of orthopedic surgery in patients with skeletal metastases is to treat spinal cord compression and existing or impending pathological fractures in an effort to relieve pain and restore function. Information on outcomes following surgery for skeletal metastases is important for the patients involved, for their families, and for treating physicians ([@CIT0022], [@CIT0008]).

Skeletal metastases from other malignancies are most often osteolytic whereas skeletal metastases from prostate cancer are most often osteoblastic, which may mean unique treatment considerations. However, little attention has been paid to survival and postoperative complications in patients with metastatic prostate lesions.

We have determined patient survival following surgery for symptomatic skeletal metastases in a large cohort of prostate cancer patients. A secondary aim was to identify patient-related and procedure-related risk factors for complications and reoperation.

Patients and methods {#ss2}
====================

This study involved a consecutive series of patients with prostate cancer who were operated for skeletal metastases from 1989 through 2010. Only patients who had their primary operation at our hospital were included in the study. All data are based on the Karolinska Skeletal Metastasis Register ([@CIT0022]). This quality-control database prospectively collects individual-based information for cancer patients admitted to the Karolinska University Hospital in Stockholm. The criterion for inclusion is surgical treatment of skeletal metastases. Data on patient identity, age, sex, primary tumor, location of metastases, type of metastases (single skeletal, multiple skeletal, or generalized), surgical procedures (method of fixation and type of implant), and postoperative complications are registered. Generalized metastases are defined as skeletal metastases in combination with visceral metastases. Pathological fractures were defined as skeletal metastases resulting in a dislocation (kyphosis or loss of height for vertebral fractures).

Neurological function in patients with spinal metastases was assessed by the Frankel classification of motor and sensory compromise. It is standard for the neurological function to be assessed preoperatively and within 2 weeks postoperatively. Data for the Frankel classification were collected retrospectively from medical records. Postoperative radiotherapy was offered routinely to all patients. 114 patients in the present analysis were included in a previous publication from our institution ([@CIT0012]).

Statistics {#ss3}
----------

Continuous descriptive statistics used median values and ranges. Kaplan-Meier analysis was used to construct the cumulative survival with 95% confidence intervals (CIs) after surgery for skeletal metastases. If patients had more than 1 surgical procedure, only the first operation was accounted for in the survival analysis.

Cox multiple regression was used to study risk factors for (1) death, (2) any complication, and (3) reoperation. The results were expressed as hazard ratios (HRs) with corresponding CIs. If a HR is \> 1, the patients at risk are dying at a faster rate or have a higher risk of complications than the patients in the reference group. The assumption of proportional hazards was investigated using graphs of the log-minus-log survivor function against log t over grouped values of the covariates. No signs of insufficient proportionality were detected in the hazard functions, and the log-log plots ran parallel for all covariates. Crude risk factors studied in the simple Cox model were age, anatomical location of the metastasis, type of metastasis (single skeletal, multiple skeletal, or generalized), and pathological fracture. All variables were adjusted for in the multiple Cox model. Wilcoxon\'s signed ranks test was used to compare preoperative and postoperative neurological function in patients with spine metastases. The level of significance was set at p ≤ 0.05. All statistical analyses were performed using the PASW statistics package version 18.

Results {#ss4}
=======

We identified 306 patients who met the inclusion criteria; these patients underwent 358 surgical procedures. No patients were excluded from analysis. 16% of the patients had more than 1 site of surgery. The median age at surgery was 72 (49--94) years. Most subjects (62%) were aged 70 years or older. At surgery, most patients had multiple skeletal metastases (73%) followed by generalized metastases (20%) ([Table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics of study patients at first surgery

                           No.
  ------------------------ -------------
  Patients                 306
   1 operation             258 (84%)
   2 operations            44 (15%)
   3 operations            4 (1%)
  Median age               72 (49--94)
  Age group                
   \< 60 years             27 (9%)
   60--69 years            90 (29%)
   \> 70 years             189 (62%)
  Metastases               
   Single skeletal         20 (7%)
   Multiple skeletal       224 (73%)
   Generalized             62 (20%)
  Pathological fractures   
   Spinal                  
    Yes                    80 (45%)
    No                     96 (55%)
   Non-spinal              
    Yes                    123 (95%)
    No                     7 (5%)

54% of the skeletal lesions were situated in the spine, followed by the femur (30%), the humerus (8%), and the pelvis (8%) ([Table 2](#T2){ref-type="table"}). Approximately half of the patients operated in the spine had a vertebral pathological fracture. The main indication for spinal operations was motor weakness due to spinal cord compression (97%); 5 patients were operated on because of painful instability. Regarding surgical procedures for spinal metastases, 58% of the cases underwent decompression in combination with stabilization ([Table 2](#T2){ref-type="table"}). The overall neurological function in patients with vertebral metastases improved after surgery (p \< 0.001). Most cases (55%) improved at least 1 Frankel grade, 39% maintained their neurological function, and 6% deteriorated ([Figure 1](#F1){ref-type="fig"}). Preoperatively, 75% of the patients were non-ambulatory (Frankel A, B, or C) and 25% were ambulatory (Frankel D or E). Postoperatively, 38% of the spine patients were non-ambulatory and 62% were ambulatory.

###### 

Anatomical locations and surgical procedures

                                    No.
  --------------------------------- -----------
  Anatomical locations              358
   Spine                            193 (54%)
    Cervical                        1
    Thoracic                        165
    Lumbar                          27
   Femur                            106 (30%)
    Femoral neck                    37
    Trochanteric                    27
    Subtrochanteric                 33
    Diaphysis                       9
   Humerus                          28 (8%)
    Proximal                        9
    Diaphysis                       17
    Distal                          2
   Pelvis                           28 (8%)
   Tibia                            2 (1%)
   Radius                           1 (0%)
  Surgical procedures               358
   Spinal                           
    Decompression                   70 (36%)
    Decompression + bone cement     11 (6%)
    Decompression + stabilization   112 (58%)
   Non-spinal                       
    Prosthesis                      95 (58%)
    Osteosynthesis                  66 (40%)
    Other                           4 (2%)
   Bone cement                      
    Yes                             125 (35%)
    No                              233 (65%)
   Curetage                         
    Yes                             26 (7%)
    No                              332 (93%)

![Pre- and postoperative neurological function in 191 patients with spinal metastases, graded according to Frankel (A = complete paraplegia, B = no motor function, C = motor function useless, D = slight motor deficit, and E = no motor deficit).](ORT-0300-9734-083-074_g001){#F1}

Non-spinal surgical procedures were most often implantation of joint prostheses (58%) followed by internal fixation with an internal-fixation device (40%). Most subjects had pathological fractures (95%), i.e. prophylactic surgery for impending fractures was only performed in 5% of the non-spinal cases ([Table 1](#T1){ref-type="table"}).

Survival {#ss5}
--------

The median survival time for the entire cohort after the first surgical procedure was 0.5 (0--16) years. The median survival time after surgery for patients with spinal metastases was 0.5 (0--16) years and for non-spinal metastases it was 0.5 (0--9) years. At the end of the study period, 94% of the patients had died. The cumulative 1- and 2-year survival after surgery was 29% (CI: 24--34) and 14% (CI: 10--18) ([Figure 2](#F2){ref-type="fig"}).

![Cumulative survival (with 95% CI) of 306 prostate cancer patients after surgery for skeletal metastases.](ORT-0300-9734-083-074_g002){#F2}

Simple Cox regression analysis revealed an increased risk of death after surgery for patients with lesions in the femur (HR 1.3), pathological fractures (HR 1.3), generalized metastases (HR 2.1), and multiple skeletal metastases (2.2). The corresponding multiple analysis revealed that older age (HR 1.4), generalized metastases (HR 2.4), and multiple skeletal metastases (HR 2.3) were significantly associated with an increased risk of death, while patients with lesions in the humerus (HR 0.7) had a significantly lower death rate ([Table 3](#T3){ref-type="table"}). We could not detect any predictor for reoperations. However, pelvic lesions (HR 2.3) were risk factors for any complication in both analyses ([Table 3](#T3){ref-type="table"}). Any complication was defined as either a reoperation or a complication that was treated non-surgically.

###### 

Risk of (1) death and (2) any complication after surgery for skeletal metastases in 306 patients with prostate cancer

                            Simple Cox regression **[^a^](#T3-N1){ref-type="fn"}**   Multiple Cox regression **[^b^](#T3-N1){ref-type="fn"}**                               
  ------------------------- -------------------------------------------------------- ---------------------------------------------------------- ------- ------ ------------ -------
  *Death (1)*                                                                                                                                                               
   Age                                                                                                                                                                      
    \> 70 years             1.3                                                      (1.0--1.6)                                                 0.07    1.4    (1.1--1.9)   0.01
    \< 70 years             Ref.                                                                                                                        Ref.                
   Anatomical location                                                                                                                                                      
    Femur                   1.3                                                      (1.0--1.7)                                                 0.05    1.2    (0.9--1.6)   0.4
    Humerus                 0.7                                                      (0.4--1.1)                                                 0.09    0.6    (0.4--1.0)   0.05
    All other               Ref.                                                                                                                        Ref.                
   Type of fracture                                                                                                                                                         
    Pathological            1.3                                                      (1.0--1.7)                                                 0.04    1.3    (1.0--1.8)   0.06
    Impending               Ref.                                                                                                                        Ref.                
   Metastases                                                                                                                                                               
    Generalized             2.1                                                      (1.2--3.6)                                                 0.006   2.4    (1.4--4.2)   0.002
    Multiple skeletal       2.2                                                      (1.3--3.6)                                                 0.002   2.3    (1.4--3.8)   0.001
    Single skeletal         Ref.                                                                                                                        Ref.                
  *Any complication*(*2)*                                                                                                                                                   
   Anatomical location                                                                                                                                                      
    Pelvis                  2.3                                                      (1.3--4.3)                                                 0.007   2.3    (1.2--4.2)   0.01
    All other               Ref.                                                                                                                        Ref.                

**^a^**Crude HR. **^b^** Adjusted HR.

HR: hazard ratio; CI: confidence interval.

Reoperations and complications {#ss6}
------------------------------

The reoperation rate was 9% (n = 31). The median time to reoperation was 0.5 (0--24) months ([Table 4](#T4){ref-type="table"}). Complications that were treated non-surgically occurred in 15% of the cases. The median time from surgery to a non-surgically treated complication was 0.2 (0--10) months ([Table 5](#T5){ref-type="table"}). The overall complication rate (for any complication) was 24%.

###### 

Reoperations (n = 31)

  --------------------------------------------------------------------------------------------------------------------
  Reason for reoperation    No., primary metastasis   Median time to reoperation (months)   Treatment
  ------------------------- ------------------------- ------------------------------------- --------------------------
  Deep wound infection      5, spine                                                        

                             3, pelvis                                                      

                             2, femur                 1.3                                   Wound revision

  Hematoma                  7, spine                  0                                     Drainage

  Material failure          3, femur                  2.5                                   Total joint replacement

  Wound dehiscence          3, spine                  1                                     Secondary wound closure

  Increasing neurological                                                                   

  symptoms                  2, spine                  0                                     Extended laminectomy

  Prosthetic dislocation    2, pelvis                 0.5                                   Open reduction\
                                                                                            Extraction of prosthesis

  Non-union                 1, femur                  24                                    Total joint arthroplasty

  Periprosthetic fracture   1, femur                  5.6                                   Osteosynthesis

  Poor initial fixation     1, femur                  0.5                                   Osteosynthesis

  Technical error           1, spine                  0.2                                   Extended laminectomy
  --------------------------------------------------------------------------------------------------------------------

###### 

Complications treated non-surgically (n = 54)

  Type of complication          No., primary metastasis   Median time to complication, months
  ----------------------------- ------------------------- -------------------------------------
  Superficial wound infection   14, spine                 
                                2, femur                  
                                1, pelvis                 0.2
  Prosthetic dislocation        8, femur                  
                                7, pelvis                 
                                1, humerus                0.5
  Pulmonary embolism            2, spine                  
                                2, femur                  
                                1, pelvis                 0.1
  Pneumonia                     4, spine                  
                                1, femur                  0.1
  Heart failure                 2, spine                  
                                1, femur                  0
  Myocardial infarction         1, spine                  
                                1, pelvis                 0
  Wound dehiscence              2, spine                  1.6
  Perioperative hypoxia                                   
  (hemiparesis)                 1, femur                  0
  Radial nerve palsy            1, humerus                0
  Stroke                        1, spine                  0
  Deep wound infection          1, femur                  0

Discussion {#ss7}
==========

Decision making regarding management of skeletal metastases is influenced by factors such as expected duration of survival, overall medical condition, rehabilitation potential, and type of operation required. The goal is to relieve pain and improve function for the maximum amount of time. Patients with a short life expectancy may not benefit from surgery due to rapid deterioration of health and difficulties in managing the postoperative rehabilitation. Some authors have argued that a postoperative lifespan of at least 2 months is required for surgery to be beneficial in extremity metastases ([@CIT0010]) and a postoperative lifespan of 3--6 months for spinal lesions ([@CIT0007], [@CIT0001], [@CIT0020]). However, these time points are highly debated, and the decision to offer surgery remains patient-specific.

The main indication for almost all spinal cases in our study was motor weakness due to spinal cord compression. [@CIT0011] described 70 patients with spinal cord compression secondary to breast cancer. The most frequent symptom was motor weakness (96%) followed by pain (94%), sensory disturbance (79%), and sphincter disturbance (61%). More than half of our patients with spinal involvement improved considerably after surgery, i.e. at least 1 Frankel grade, and approximately 40% maintained their neurological function. These results are similar to those from a recent randomized study, which demonstrated that decompressive surgery in combination with radiotherapy in patients with metastatic epidural cord compression was superior to radiotherapy alone ([@CIT0018]).

Several studies have identified prognostic clinical variables that may help to identify patients with a limited expected lifespan after surgery due to skeletal metastases from various cancer types. Pathological fractures, visceral metastases, low hemoglobin level, number of skeletal metastases, and lung cancer as the primary tumor are examples of independent negative prognostic factors for postoperative survival ([@CIT0002], [@CIT0009], [@CIT0014], [@CIT0013], [@CIT0008]).

Nørgaard et al. (2010) presented survival data on patients with prostate cancer in a large population-based cohort study. 1-year survival was 87% in patients without skeletal metastasis and 47% in those with skeletal metastasis. The combination of bone metastasis and skeletal-related events reduced the 1-year survival rate to 40%. [@CIT0025] presented survival data on 260 patients with spine metastases from prostate cancer, treated either with radiotherapy or surgery. They found a 1-year survival rate of approximately 35%, which is comparable to our findings.

We identified several predictors of survival. Younger patients had longer survival after surgery, which has also been described in patients after surgery for skeletal lesions from renal cell carcinoma ([@CIT0021]). [@CIT0015] showed that the extent of metastatic skeletal lesions (percentage of positive area on a bone scan) is an independent predictor of death from disease in patients with prostate cancer. We found that patients with a solitary bone metastasis (as compared to multiple metastases) had better survival, which has been reported previously ([@CIT0023], [@CIT0021]). Skeletal lesions in the humerus were also found to be a positive predictor of survival, a finding for which there is no immediate explanation. This could represent selection bias; for example, unstable fractures in the lower limbs may pose such a significant problem for patients and caregivers that surgical stabilization may be appropriate even when patients have a limited expectation of survival. However, most surgeons at our center do not usually stabilize impending pathological humerus fractures in patients with short expected survival, and as a result, such patients were not included in this study.

We have confirmed the findings of other authors that pathological fractures negatively influence survival ([@CIT0017], [@CIT0008]). However, only 7 of 130 patients with non-spinal metastases underwent prophylactic stabilization. At our institution, surgery is generally recommended for patients with disabling skeletal lesions in addition to those at risk of fracture using generally accepted criteria. Although efforts have been made to better predict fracture sites and avoid an actual fracture ([@CIT0006]), it is unclear whether prophylactic surgery itself confers a survival benefit. Prophylactic surgery was performed in only 5% of our cases. Most patients sustained pathological fractures, which tend to occur later in the disease process in a similar fashion to other oncological diagnoses.

It is often more difficult to treat a pathological fracture than a traumatic fracture. Bone-healing is often impaired due to extensive bone destruction, a catabolic state, and the effects of radiotherapy. The observed reoperation rate of 9% is comparable to previously reported surgical failure rates in pathological fractures ([@CIT0024], [@CIT0023]). In addition, patients with metastases confined to bone (without soft tissue extension) had a lower risk of both reoperation and any complication than did those with generalized metastases.

In addition to complications leading to reoperation, one must also consider those treated nonoperatively. Periacetabular lesions requiring a combination of acetabular metal reinforcement ring and hip arthroplasty emerged as an independent predictor for a complication. This is largely due to the relatively high frequency of hip dislocations, which were treated with closed reduction procedures (7 out of 28) in this subgroup.

Limitations of our study included the lack of information regarding whether adjuvant treatment such as androgen suppression, cytotoxic chemotherapy, or radiation therapy was used. However, at our center, adjuvant radiation therapy is generally used in all patients with surgically treated metastatic bone disease, which is (ideally) started 10--14 days after surgery to allow wound healing.

In conclusion, surgery for vertebral metastases may be the best alternative in patients who are expected to live for at least another 2--3 months, especially if surgery is likely to result in a functional improvement. The patient can, for example, avoid being bedridden and perhaps regain/maintain the ability to ambulate independently. We believe that stabilization of long bone fractures is almost always justified unless the patient has reached a terminal stage and death is imminent.
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